Navigation Links
Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/22/2013

SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 4:00 PM Eastern Time in New York.  

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.mirati.com.  Replays of the presentation will be available at the same location for 30 days following the conference.

About Mirati Therapeutics
Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using its proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates, including MGCD265 and MGCD516, which are orally bioavailable, multi-targeted kinase inhibitors with distinct target profiles, and mocetinostat, an orally bio-available, spectrum-selective histone deacetylase inibitor. More information is available at www.mirati.com.


'/>"/>
SOURCE Mirati Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
2. Mirati Therapeutics Prices Public Offering Of Common Stock
3. Inhibikase Therapeutics, Inc. Elects Anthony Zook To The Board Of Directors
4. Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
5. Lightlake Therapeutics to Present at 6th Annual LD MICRO Conference
6. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
7. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
8. Prostate Cancer Therapeutics Market Worth $8.0 billion by 2019
9. Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
10. Cell Therapeutics to Host Conference Call Today, Friday, November 15, 2013, at 8:30 a.m. Eastern Time, to Discuss Pacritinib Partnership
11. Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief ... advancements to physician colleagues, skilled nursing facility medical directors and other clinicians at ... of Wound Care." , "At many of these conferences we get to educate ...
Breaking Medicine News(10 mins):